Research Frontiers What are the differences in the benefits of targeted therapy in elderly mRCC patients?

A total of 314 patient data were included in the final data analysis, of which 173 (55%) patients were treated in the P1 phase and 141 (45%) were treated
in the P2 phase.
The median follow-up was 33.
8 months (range: 1-181.
6 months) for the P1 phase and 27.
3 months (range: 0.
6-179.
5 months)
for the P2 phase.

The median OS for the overall cohort was 39.
7 months (95% CI 33.
1 to 46.
3 months); The median OS for P1 and P2 phases was 35.
1 months (95% CI 28.
3 to 41.
9 months) and 59.
1 months (95% CI 36.
1 to 82.
2 months, Log-rank:p=0.
002),
respectively.

Fig.
1 OS results at different treatment periods

Analysis of patients in different age groups showed that the median OS was 38.
1 months (95% CI 28.
6 to 47.
6 months) in Group 1, 42.
9 months (95% CI 29.
5 to 56.
3 months) in Group 2, and 27.
3 months (95% CI 12.
8 to 41.
8 months)
in Group 3.
There was no statistically significant
difference between groups in OS.
Comparing OS in different age groups and different treatment periods, it was found that patients in group 2 had the greatest improvement in OS, 59.
1 months (95% CI 22.
9-95.
3 months) vs 40.
1 months (95% CI 30.
5-49.
7 months), Log-rank p=0.
034
.
A similar trend was observed in Group 3 (Log-rank p=0.
056).

Fig.
2 OS results of P1 and P2 stages in different age groups (A: group 1; B: Group 2; C: Group 3)

The results of multivariate analysis in stage 1 showed that age > 75 years (logistic regression p=0.
002), histological non-ccRCC (logistic regression p=0.
002), high MSKCC score (p=0.
012), and ≥2 metastases (logistic regression p=0.
018) were independent risk factors for
OS 。 Multivariate analysis of Phase 2 showed that only ECOG PS≥1 (logistic regression p<0.
001) affected OS<b11>.
Therefore, the age factor in stage 2 cannot be recognized as increasing the risk
of OS.

Fig.
3 Analysis of risk factors for death